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Introduction
The traditional models of breast cancer development are
based on morphological studies and suggest the transi-
tion from a normal epithelial cell via hyperplasia and atypi-
cal hyperplasia (Fig.1a) to ductal carcinoma in situ
(DCIS). These studies were supported by analogy with
mouse mammary tumour models and by epidemiological
studies, which showed that the risk for breast cancer
increased with the rate of proliferation and atypia in
breast biopsies. Although proliferation per se is a proba-
ble risk factor for breast cancer, in our view the only intra-
ductal proliferation that can be considered as an obligate
precursor to every invasive breast cancer is carcinoma in
situ. This implies that every invasive carcinoma initially
develops as a carcinoma in situ (but this does not imply
that every carcinoma in situ will progress to invasive
cancer). Within the category of carcinoma in situ are
lobular carcinoma in situ (LCIS) and DCIS. It is well
established that DCIS can be further subdivided based
on cytonuclear characteristics, growth pattern and
absence or presence of necrosis, and that also specific
genetic change indicates that there are different path-
ways for development of these in situ carcinomas.
There is, however, no direct evidence that epithelial hyper-
plasia and atypical hyperplasia are precursors to carci-
noma  in situ or invasive carcinoma, neither from
epidemiological, nor from histopathological or molecular
biological studies. Therefore, the proposal of the terms
mammary intraepithelial neoplasia [1] and ductal intra-
epithelial hyperplasia [2], embodying the concept of con-
tinuous progression from epithelial hyperplasia to
carcinoma in situ, should not be adopted (Fig.1b). In addi-
tion, there is significant interobserver variability in diagnos-
ing atypical ductal hyperplasia (ADH) [3], which is not
resolved by giving these lesions a different name.
Lastly, it is very probable that the nature of the rare lesion
originally classified as ADH has changed: in the pre-
mammography era this lesion was detected by chance in
otherwise benign biopsies, whereas nowadays this lesion
is most commonly diagnosed in radioguided biopsies
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Abstract
In this review, we comment on the reasons for disagreement in the concepts, diagnosis and
classifications of pre-invasive intraductal proliferations. In view of these disagreements, our proposal is
to distinguish epithelial hyperplasia, lobular carcinoma in situ and ductal carcinoma in situ, and to
abandon the use of poorly reproducible categories, such as atypical ductal hyperplasia or ductal
intraepithelial neoplasia, followed by a number to indicate the degree of proliferation and atypia, as
these are not practical for clinical decision making, nor for studies aimed at improving the
understanding of breast cancer development. If there is doubt about the classification of an intraductal
proliferation, a differential diagnosis and the reason for and degree of uncertainty should be given,
rather than categorizing a proliferation as atypical.
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taken because of microcalcifications, or from the lesions
detected by ductal lavage.
The following text sets out arguments to abandon some of
the categories used or suggested to classify intraductal
proliferations, especially ADH, the so-called clinging type
of ADH, and atypical lobular hyperplasia (ALH). We will
also comment on the diagnostic problems and therapeutic
consequences of intraductal proliferations in core biop-
sies, and on the claimed role of ductal lavage in the
assessment of breast cancer risk.
Atypical ductal hyperplasia
ADH in the presently used nomenclature is viewed as a
risk factor for and not as a direct precursor of invasive
breast cancer [4]. However, the first studies, at the begin-
ning of the 20th century, leading to the concept of ADH
were performed to find precancerous lesions in the breast.
The method mainly used for such studies was to examine
breast tissue surrounding invasive breast carcinomas.
These studies revealed the presence of various types of
intraductal proliferations and attempts were made to cate-
gorize these; the term ‘atypical hyperplasia’ or ‘hyperplasia
with atypia’ was introduced and was used mainly to indi-
cate the presence of proliferations of epithelial cells with
cytonuclear atypia. Wellings et al. have reviewed the older
literature on this subject and build on it for their own
studies on possible precancerous lesions [5]. Wellings et
al. write that the rationale for their studies was based on
their prior experience with rodent models, most notably
the epithelial proliferations seen in mice with mouse
mammary tumour virus induced lesions of the breast.
These investigators also started to use a subgross sam-
pling technique of breasts with cancer and breasts
without malignancy. They found ‘atypical lobules’ (AL)
more commonly in cancerous breasts compared to non-
cancerous breasts. They summarize the characteristics of
AL as follows: ‘a) It was more common in cancerous
breasts or in those contralateral to cancer than in breasts
not so identified; b) it had lobular morphology and was a
terminal structure on the mammary tree; c) it tended to
persist after the menopause, whereas normal lobules
usually atrophied; d) it showed variable degrees of anapla-
sia forming an arbitrary continuum from normal lobules to
ductal carcinoma in situ; and e) as AL progressed to
DCIS, the unfolded lobule resembled a duct which gave
the false impression that DCIS was a ductal lesion. The
morphologic evidence supported the hypothesis that the
lesions herein called AL were derived from TDLU [terminal
ductal lobular unit] and were precancerous.’ [5]
Another important area of research, pioneered by Page
and co-workers, is the review of biopsies of benign breast
disease from women with long-term follow-up [4]. Using a
cohort-based approach and, more commonly, a case-
control approach, the histopathological findings in biop-
sies from women who developed breast cancer were
compared to those from women who remained free of
disease. In this way, various lesions have been associated
with an increased risk of developing breast cancer, includ-
ing radial scars [6], fibroadenomas [7], and various forms
of epithelial hyperplasia, most notably the lesion they cate-
gorized as ADH [8]. The increased risk associated with
these lesions was found for both breasts (and not only for
the biopsy site), leading to the postulate that these lesions
were ‘non-obligate precursors’ of breast cancer. The
attempts to define categories of intraductal proliferations
thus largely stems from the search for precancerous
lesions, and the search for lesions associated with
increased risk. The application of the terminology emerg-
ing from this work in diagnostic breast pathology has
caused problems, most notably in producing appropriate
definitions and applying these with acceptable inter-
observer variability.
It is a fact of life that some of the intraductal proliferations
can pose diagnostic difficulties. The most frequently
Figure 1
The multistep development of invasive breast cancer. (a) This model is
often used to explain how breast cancer develops. The way in which
the model is drawn suggests that epithelial hyperplasia is a direct
precursor to atypical ductal hyperplasia (ADH) and ductal carcinoma in
situ (DCIS). (b) There is no proof that epithelial hyperplasia is a direct
precursor of ADH and DCIS, and that there is a continuum of
alterations leading from epithelial hyperplasia to DCIS.
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encountered differential diagnostic problem is whether a
lesion represents epithelial hyperplasia or carcinoma in
situ. This has led to the application of the findings from the
work described above to define a category of intraductal
proliferations that is intermediate between epithelial hyper-
plasia and DCIS, and which has been termed ADH.
The most commonly used definition is that ADH represents
‘a proliferative lesion that fulfils some but not all criteria for
a diagnosis of low grade, non-comedo type DCIS.’ In the
original series ADH was described as usually unifocal and
small, often less than 1mm (or two spaces) in size [4].
In trying to refine these criteria, there have been many con-
tributions in the literature, which are summarized below:
‘ADH has as its upper boundary the most minimal lesions
recognized as DCIS, i.e., the low grade (non-comedo)
lesions, largely cribriform in pattern. The lower boundary of
ADH is defined by examples of florid hyperplasia with
focal areas of cellular uniformity and even placement of
cells’ [9]. Although these authors stress that their criteria
for distinguishing ordinary hyperplasia and DCIS from
ADH are not placed on a continuous scale, application of
their above-mentioned description will not be helpful in
separating these lesions.
As a characteristic feature of ADH ‘partial involvement’ of
a duct has been described. This means that a duct con-
tains a focus of a monotonous rigid cribriform or
micropapillary proliferation, whereas the duct lining con-
sists of one layer of polarized cells with more cytoplasm
and vesicular nuclei. In this way also extensive monoto-
nous proliferations with clinging, micropapillary and only
focal cribriform patterns can be categorized as ADH.
As the extent of the lesion is the main determinant separat-
ing most examples of ADH from DCIS, an upper size limit
was defined [10]. However, this limit varied for different
situations (2–3mm for ‘standard’ ADH, up to 4mm for
apocrine ADH in papilloma), and was mainly applied for
those lesions showing all the characteristic features of low
grade DCIS.
It is questionable whether these refinements lead to
improved interobserver variability in the diagnosis of ADH.
Several studies show that the interobserver agreement on
the diagnosis of ADH is very poor, even when consensus
about diagnostic criteria exists [3].
A very important factor that is often ignored in the recent
publications on ADH is the clinical context that has led to
taking a breast biopsy. If a tumour mass is present and an
intraductal proliferation is noted at histological examina-
tion, the biopsy is usually not representative for the lesion.
If the mass represents an invasive breast carcinoma,
accompanied by a small amount of well-differentiated
DCIS, it is possible to obtain a small amount of well-differ-
entiated DCIS in a core needle biopsy, which, according
to most present classification systems, would be labelled
ADH. This is not a very practical approach: it is better to
note that the biopsy is most likely not representative of the
lesion and that the presence of a small amount of well-dif-
ferentiated DCIS leads one to suspect that the surround-
ings of an invasive carcinoma have been biopsied.
Some reports also describe the presence of ADH adjacent
to DCIS. This does not make any sense: the intraductal
proliferation with some but maybe not all criteria for DCIS
that is present adjacent to DCIS will, in most instances, be
the same clonal proliferation as the dominant focus of
DCIS, and should therefore be classified as such.
So, what of the remaining problematic situations with
diagnosis? A biopsy may contain only a very small amount
of DCIS, or a biopsy may show an intraductal proliferation
that cannot be easily classified as DCIS or epithelial
hyperplasia. If a very small amount of DCIS is found, our
proposal is simply to make the diagnosis of DCIS and
specify that the lesion is very small. When an intraductal
proliferation cannot be classified with certainty, this should
be indicated; for example, the differential diagnosis for
intraductal epithelial proliferation would be well-differenti-
ated DCIS or epithelial hyperplasia.
Atypical lobular hyperplasia
For ALH the situation has become relatively simple.
According to most definitions, ALH is ‘a small amount of
LCIS’. The original follow-up studies suggested differ-
ences in risk between ALH and LCIS, and this was the
main reason to distinguish these lesions. All cases of ALH
also stain negative for E-cadherin, indicating that the
genetic alteration that is characteristic for LCIS is also
present in these very small lesions [11]. Moreover, with
longer follow-up the risk of both lesions becomes more or
less comparable [12]. Therefore, there is no place for the
term ALH.
There has also been extensive discussion about whether
the term LCIS should be maintained. As with other intra-
ductal proliferations, an important question in these dis-
cussions was whether LCIS is a precursor lesion or a
determinant of risk. Again, the early epidemiological
studies suggested an increased risk of developing cancer
anywhere in both breasts, consistent with the concept that
LCIS is a determinant of risk. However, recently updated
prospective follow-up series [12,13] show occurrence of
invasive cancer preferably in the ipsilateral breast at the
site of biopsied LCIS, consistent with LCIS being a pre-
cursor. The ultimate risk associated with this lesion is not
lower than that for well-differentiated DCIS. We therefore
prefer to use the term LCIS, complemented by additional
information on the extent of the lesion.
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Atypical ductal hyperplasia of the clinging
type; flat epithelial atypia
In recent years, screening with mammography is being
performed with increasing frequency to detect breast
cancer at an early stage. Using mammography screening,
microcalcifications are a relatively frequent finding, leading
to guide-wired excisions or core needle biopsies from
these areas of microcalcification. As a result, breast
lesions leading to microcalcifications are seen by patholo-
gists with increasing frequency.
A particular lesion detected by microcalcifications is
described by Fraser et al. [14]: ‘We have noted in breast
biopsies performed for microcalcifications a spectrum of
lesions in the terminal duct lobular unit characterised by
columnar epithelial cells with prominent apical cytoplas-
mic snouts, intraluminal secretions, and varying degrees
of nuclear atypia and architectural complexity. The
appearance of some of these lesions is worrisome, but
diagnostic difficulties arise because the histological fea-
tures do not fulfil established criteria for the diagnosis of
atypical ductal hyperplasia or ductal carcinoma in situ
(DCIS). We have termed such lesions columnar alter-
ation with prominent apical snouts and secretions
(CAPSS).’
However, this lesion was by no means new; for example, a
description was given in the seminal book on breast
disease by Azzopardi [15]: ‘There is another, more
common form of clinging carcinoma in which the lesion
shows no evidence of having originated as a comedo
cancer and this is indeed the most difficult type to recog-
nize. The involved structures are lined by a single or a few
layers of neoplastic cells…, showing orientation towards
the lumen, whilst there is no obvious necrosis.’ In his
description, Azzopardi points out that usually several
lobules are involved; that the cytoplasm may show lumenal
blebbing; and that the myoepithelial layer is usually incon-
spicuous (in contrast to adenosis), and that trabecular
bars and bridges may be present, which are helpful in
diagnosing this lesion. He even describes the granular cal-
cifications originating from inspissated lumenal contents,
which are the reason for pick-up on mammography. The
microcalcifications that lead to the excision of these
lesions are usually fine and granular with multinodular/
lobular arrangements, and often involve an area of several
centimetres.
There is no agreement about the nature of this lesion; con-
cepts vary from an ordinary benign change, to the first rec-
ognizable stage of well-differentiated DCIS. This lack of
consensus is reflected in the different terms used in litera-
ture: atypical lobule; cystic change; atypical cystic alter-
ation; flat epithelial hyperplasia; and the aforementioned
columnar alteration with prominent apical snouts and
secretions and clinging type of DCIS.
We consider this lesion as well-differentiated DCIS cling-
ing/micropapillary type. The arguments that this is a neo-
plasm rather than a form of hyperplasia include: these
lesions have a similar distribution to other forms of DCIS;
ducts and lobules are affected in a continuous way; and
when these lesions become large, they involve only one
segment of the breast.
In virtually every case of well-differentiated DCIS, there are
parts of the lesion showing the exact same morphology as
well-differentiated DCIS clinging/micropapillary type
(Fig.2). The cytonuclear morphology of the cells with a
clinging growth pattern in these cases is identical to that
of the areas with a cribriform growth pattern, although dif-
ferences in cell size as a result of cell orientation (cross in
the cribriform centres, perpendicular in the clinging duct
lining) may suggest two cell types. Clinging DCIS is often
present in and around tubular carcinoma, especially in
cases with multiple invasive foci, and seems to be the non-
invasive precursor of that carcinoma. In our opinion, all
cases of fully developed cribriform DCIS and many cases
of invasive ductal carcinoma grade 1/tubular carcinoma
develop via well-differentiated DCIS clinging/micropapil-
lary type.
The clinical question is what to do when, in a diagnostic
biopsy, only well-differentiated DCIS clinging/micropapil-
lary type is detected. At present, it is not known what per-
centage of these lesions will progress to become more
advanced lesions and how long this progression takes. In
view of the lack of consensus in recognizing and typing
these lesions, which were only rarely biopsied in the pre-
mammography era, there is limited clinical experience to
form the basis for clinical decision making.
Eusebi et al. found that, at a mean follow-up of 17.5 years,
only two out of 32 cases of pure clinging well-differenti-
ated DCIS treated by incision biopsy alone recurred; in
both cases the recurrence was a well-differentiated DCIS
[16]. The European Organization for Research and Treat-
ment of Cancer has performed a randomized clinical trial,
comparing excision alone with excision followed by radio-
therapy. The cases of DCIS in this study were classified
histologically by central pathology review; the recurrence
rate was evaluated at a median follow-up of 5.4 years [17].
No recurrences were observed in the 59 patients with
well-differentiated DCIS with a clinging architecture. A low
rate of invasive recurrence was also found in well-differen-
tiated DCIS with a micropapillary growth pattern (7 out of
98 cases), whereas in well-differentiated cribriform DCIS
the rate was similar to that in poorly differentiated DCIS.
This suggests that these architectural patterns reflect a
spectrum of development from relatively innocent clinging
lesions to those with a fully developed cribriform DCIS;
lesions with a micropapillary growth pattern can be con-
sidered an intermediate in this pathway.
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Clearly, more data are required to optimize clinical man-
agement for these patients. At this moment, follow-up of
these patients with annual mammography seems a rea-
sonable option. Excision of these lesions with clear
margins is often difficult to achieve because the lesions
are often extensive. Breast ablation appears to be
overtreatment for these patients (a situation very similar to
LCIS; actually, these lesions also co-exist quite frequently
with LCIS).
Concerning the preferable terminology for these lesions,
flat epithelial atypia has been proposed. This term avoids
the term ‘cancer’ in the diagnosis, thus reducing patient
stress and surgical overtreatment. From a conceptual
point of view, however, we would prefer the term ‘well-dif-
ferentiated clinging type of DCIS’. When reporting this
diagnosis, its relatively innocent nature should be
stressed.
Risk assessment for breast cancer by ductal
lavage and ‘random’ fine needle aspiration
Recently, several studies reported on the assessment of
risk of development of breast cancer based on cyto-
nuclear characteristics of cells obtained by minimal or
non-invasive methods. Ductal lavage was used to obtain
cells from the ductal system of the breast. Cytological
examination was used to identify ‘atypical ductal hyper-
plasia’, or mildly and markedly atypical cells in these
specimens. Likewise, multiple fine needle aspirations
(FNA), taken randomly from the breasts of asymptomatic
women, have been evaluated to detect cytological
changes indicative of epithelial hyperplasia with or
without atypia.
In 1990, Skolnick et al. reported on FNA, randomly taken
from both breasts of women with and without a family
history of breast cancer [18]. They reported proliferative
breast disease to be more frequent in women with a family
history of breast cancer. In response, Page and Dupont
commented that proliferative breast disease cannot be
reliably assessed on FNA, and that ADH certainly cannot
be identified in this way [19].
It is, of course, not to be expected that ADH can be diag-
nosed based on cytological specimens. Because ADH is
by definition a lesion of small extent and usually unifocal
and because the interobserver variability is already high for
the histological diagnosis, it is clear that cytological exami-
nation to diagnose ADH will perform even worse, espe-
cially as architectural features (which cannot be evaluated
at cytological evaluation) play an important role in reaching
this diagnosis. Evaluation of epithelial hyperplasia in cyto-
logical material has the same drawbacks: the criterion of
hyperplasia is multilayered ductal lining as a result of
intralumenal cell proliferation. High cellularity in FNAs
does not necessarily imply epithelial hyperplasia.
Available online http://breast-cancer-research.com/content/5/5/269
Figure 2
Three histological sections from one lesion. In our opinion, this lesion
should be diagnosed as well-differentiated ductal carcinoma in situ
(DCIS). These lesions are usually large (several centimetres in
diameter). Well-differentiated DCIS often shows various growth
patterns: clinging; micropapillary; cribriform. Every well developed
cribriform DCIS [as shown in (c)] also contains areas with a clinging
growth pattern (a). (a) Often diagnosed as columnar alteration with
prominent apical snouts and secretions. (b) Often diagnosed as
atypical ductal hyperplasia. These lesions are all in the spectrum of
neoplasms characterized by a clonal proliferation of epithelial cells with
monotonous round to oval nuclei, and for this reason they can best be
classified as well-differentiated DCIS.274
The same limitations apply to studies of ductal lavage or
nipple fluid cytology. Each breast has approximately
15 segments, all ending in a separate collecting duct in the
nipple. When ductal lavage is performed, usually only two
to three of the collecting ducts are sampled. The sampled
collecting ducts are selected on the basis of production of
some fluid applying a vacuum. The unproven hypothesis is
that ductal trees that do not produce some fluid on apply-
ing a vacuum will not contain epithelial hyperplasia. In any
case, it is important to realize that only a small proportion of
the ductal system of the breast is sampled by ductal
lavage. To provide an indication of the design and outcome
of such studies, one of the few large studies on fluid from
the ductal system is from Wrensch and co-workers [20].
They collected nipple aspirate fluid from two series of
women; the median times of follow-up were 21 years and
9 years, respectively, and breast cancer incidences were
7.8% (285 cases in the 3633 women for whom breast
cancer status could be determined) and 3.5% (115 of
3271), respectively. Compared with women from whom no
fluid was obtained, incidences and adjusted relative risks
for women in group 1 with epithelial hyperplasia and atypi-
cal hyperplasia in aspirates were slightly elevated, with very
wide confidence intervals [20].
In summary, as indicated by Khan et al. ‘data regarding the
impact of these techniques on the detection of significant
breast disease are very scant. It is important at the outset
of the assessment of this new technology that breast
cancer clinicians and clinical researchers think carefully
about the standards of evidence that need to be met
regarding the benefits of these procedures before they are
widely adopted.’ [21]
Discussion
As a result of the confusion with respect to the classification
of intraductal proliferations of the breast there have been
several proposals to introduce new classification systems,
such as mammary or ductal intraepithelial proliferation. In
contrast, our proposal is to return to an older classification
system, where the only diagnostic subgroups are carcinoma
in situ and epithelial hyperplasia. In this brief overview, we
have indicated that there is no good underlying scientific
evidence for the introduction or use of other diagnostic cat-
egories, nor is there evidence that the use of other diagnos-
tic categories resolves the problems with interobserver
variability in classifying intraductal breast lesions.
The classification of intraductal breast lesions is important
in surgical pathology, where treatment decisions are
based on diagnostic classification; in addition, the classifi-
cation system forms the basis for genetic studies aimed at
elucidating the multistep development of breast cancer.
For clinical purposes, the majority of intraductal prolifera-
tions can be categorized as either (benign) epithelial
hyperplasia or carcinoma in situ (usually ductal; i.e. DCIS).
For the small group of lesions where no definite judgement
can be given, the problem is usually that there is doubt
between well-differentiated DCIS or epithelial hyperplasia.
Instead of, for example, seeking outside consultation, these
lesions are now often diagnosed as ADH, a diagnosis
associated with very high interobserver variability, even
among expert breast pathologists. When a differential diag-
nosis between well-differentiated DCIS and epithelial
hyperplasia is given, this should result in combining the
clinical, radiological and pathological findings in a multidis-
ciplinary discussion, which will often resolve the problem or
lead to a practical clinical approach.
A good example of the presence of a specific genetic
alteration in a specific type of intraductal proliferation is
the inactivation of E-cadherin in lobular neoplasia. It may
well be that, in the future, genetic classification will greatly
help in classifying other intraductal proliferations as well.
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